BBIO vs. BPMC, RETA, TPTX, PRGO, BHVN, ALNY, TEVA, GMAB, RPRX, and BGNE
Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Blueprint Medicines (BPMC), Reata Pharmaceuticals (RETA), Turning Point Therapeutics (TPTX), Perrigo (PRGO), Biohaven (BHVN), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BeiGene (BGNE).
BridgeBio Pharma (NASDAQ:BBIO) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
In the previous week, BridgeBio Pharma had 14 more articles in the media than Blueprint Medicines. MarketBeat recorded 21 mentions for BridgeBio Pharma and 7 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.05 beat BridgeBio Pharma's score of 0.37 indicating that Blueprint Medicines is being referred to more favorably in the news media.
BridgeBio Pharma currently has a consensus target price of $47.62, suggesting a potential upside of 65.97%. Blueprint Medicines has a consensus target price of $103.94, suggesting a potential downside of 1.42%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe BridgeBio Pharma is more favorable than Blueprint Medicines.
Blueprint Medicines received 375 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 68.25% of users gave BridgeBio Pharma an outperform vote while only 67.84% of users gave Blueprint Medicines an outperform vote.
Blueprint Medicines has higher revenue and earnings than BridgeBio Pharma. Blueprint Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
99.9% of BridgeBio Pharma shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Blueprint Medicines has a net margin of -102.15% compared to BridgeBio Pharma's net margin of -246.24%. BridgeBio Pharma's return on equity of 0.00% beat Blueprint Medicines' return on equity.
BridgeBio Pharma has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.
Summary
BridgeBio Pharma beats Blueprint Medicines on 11 of the 17 factors compared between the two stocks.
Get BridgeBio Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BridgeBio Pharma Competitors List
Related Companies and Tools
